Zydus Therapeutics Inc.
Clinical trials sponsored by Zydus Therapeutics Inc., explained in plain language.
-
New hope for PBC patients: phase 3 trial of saroglitazar launches
Disease control Not yet recruitingThis study tests a new drug, saroglitazar magnesium, in 89 adults with primary biliary cholangitis (PBC) who did not get enough benefit from or could not tolerate standard treatment (UDCA). The goal is to see if the drug can lower a key liver enzyme (alkaline phosphatase) to norm…
Phase: PHASE3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for rare liver disease: drug aims to slow damage
Disease control Not yet recruitingThis long-term study tests whether saroglitazar magnesium can prevent serious liver complications in people with primary biliary cholangitis (PBC), a rare autoimmune liver disease. About 386 adults already on standard treatment will receive either the drug or a placebo. The goal …
Phase: PHASE3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC